An Overview of Mucosa-Associated Protozoa: Challenges in Chemotherapy and Future Perspectives

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2022 May 13

PMID 35548465

Authors

Helena Lucia Carneiro Santos

Karina M Rebello

Affiliations

Soon will be listed here.

Abstract

Parasitic infections caused by protozoans that infect the mucosal surfaces are widely neglected worldwide. Collectively, spp. and infect more than a billion people in the world, being a public health problem mainly in developing countries. However, the exact incidence and prevalence data depend on the population examined. These parasites ultimately cause pathologies that culminate in liver abscesses, malabsorption syndrome, vaginitis, and urethritis, respectively. Despite this, the antimicrobial agents currently used to treat these diseases are limited and often associated with adverse side effects and refractory cases due to the development of resistant parasites. The paucity of drug treatments, absence of vaccines and increasing problems of drug resistance are major concerns for their control and eradication. Herein, potential candidates are reviewed with the overall aim of determining the knowledge gaps and suggest future perspectives for research. This review focuses on this public health problem and focuses on the progress of drug repositioning as a potential strategy for the treatment of mucosal parasites.

Citing Articles

Exploration of innovative drug repurposing strategies for combating human protozoan diseases: Advances, challenges, and opportunities.

Hu S, Batool Z, Zheng X, Yang Y, Ullah A, Shen B J Pharm Anal. 2025; 15(1):101084.

PMID: 39896318 PMC: 11786068. DOI: 10.1016/j.jpha.2024.101084.

Dehydrothyrsiferol Against Cutaneous Leishmaniasis: Treatment Outcome in a Murine Model.

Lopez-Arencibia A, Bethencourt-Estrella C, San Nicolas-Hernandez D, Rodriguez-Exposito R, Dominguez-de-Barros A, Salazar-Villatoro L Mar Drugs. 2025; 23(1.

PMID: 39852516 PMC: 11766930. DOI: 10.3390/md23010013.

Liver parasites: A global endemic and journey from infestation to intervention.

Shahid Y, Emman B, Abid S World J Gastroenterol. 2025; 31(1):101360.

PMID: 39777245 PMC: 11684182. DOI: 10.3748/wjg.v31.i1.101360.

Antiprotozoal Activity Against and of Cyclopeptides Isolated from Saff.

Murrieta-Dionicio U, Calzada F, Barbosa E, Valdes M, Reyes-Trejo B, Zuleta-Prada H Molecules. 2024; 29(23).

PMID: 39683795 PMC: 11643917. DOI: 10.3390/molecules29235636.

Childhood Intestinal Parasitic Reinfection, Sanitation and Hygiene Practice in Eastern Ethiopia: Case Control Study.

Gebru H, Deyessa N, Medhin G, Kloos H Infect Drug Resist. 2024; 17:1791-1802.

PMID: 38752169 PMC: 11094539. DOI: 10.2147/IDR.S455037.

References

Abubakar I, Aliyu S, Arumugam C, Hunter P, Usman N . Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev. 2007; (1):CD004932. DOI: 10.1002/14651858.CD004932.pub2. View

Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

Huston C . The Clofazimine for Treatment of Cryptosporidiosis in HIV-Infected Adults (CRYPTOFAZ) and Lessons Learned for Anticryptosporidial Drug Development. Clin Infect Dis. 2020; 73(2):192-194. PMC: 8427724. DOI: 10.1093/cid/ciaa425. View

Sharma P, Khurana S, Sharma A, Sehgal R, Malla N . Presence of intracellular viruses in human Cryptosporidium isolates. Ann Parasitol. 2016; 62(2):139-47. DOI: 10.17420/ap6202.46. View

Leung A, Leung A, Wong A, Sergi C, Kam J . Giardiasis: An Overview. Recent Pat Inflamm Allergy Drug Discov. 2019; 13(2):134-143. DOI: 10.2174/1872213X13666190618124901. View

Feng J, Zhang Y, McManus S, Ristroph K, Lu H, Gong K . Rapid Recovery of Clofazimine-Loaded Nanoparticles with Long-Term Storage Stability as Anti- Therapy. ACS Appl Nano Mater. 2018; 1(5):2184-2194. PMC: 5999231. DOI: 10.1021/acsanm.8b00234. View

Nillius D, Muller J, Muller N . Nitroreductase (GlNR1) increases susceptibility of Giardia lamblia and Escherichia coli to nitro drugs. J Antimicrob Chemother. 2011; 66(5):1029-35. DOI: 10.1093/jac/dkr029. View

Painter J, Hlavsa M, Collier S, Xiao L, Yoder J . Cryptosporidiosis surveillance -- United States, 2011-2012. MMWR Suppl. 2015; 64(3):1-14. View

Baragana B, Forte B, Choi R, Hewitt S, Bueren-Calabuig J, Pisco J . Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis. Proc Natl Acad Sci U S A. 2019; 116(14):7015-7020. PMC: 6452685. DOI: 10.1073/pnas.1814685116. View

10.

Bouma M, Snowdon D, Fairlamb A, Ackers J . Activity of disulfiram (bis(diethylthiocarbamoyl)disulphide) and ditiocarb (diethyldithiocarbamate) against metronidazole-sensitive and -resistant Trichomonas vaginalis and Tritrichomonas foetus. J Antimicrob Chemother. 1999; 42(6):817-20. DOI: 10.1093/jac/42.6.817. View

11.

Schmid G, Narcisi E, Mosure D, Secor W, Higgins J, Moreno H . Prevalence of metronidazole-resistant Trichomonas vaginalis in a gynecology clinic. J Reprod Med. 2001; 46(6):545-9. View

12.

Shirley D, Sharma I, Warren C, Moonah S . Drug Repurposing of the Alcohol Abuse Medication Disulfiram as an Anti-Parasitic Agent. Front Cell Infect Microbiol. 2021; 11:633194. PMC: 7991622. DOI: 10.3389/fcimb.2021.633194. View

13.

Upcroft J, Upcroft P . Drug resistance and Giardia. Parasitol Today. 1993; 9(5):187-90. DOI: 10.1016/0169-4758(93)90144-5. View

14.

Duque-Montano B, Gomez-Caro L, Sanchez-Sanchez M, Monge A, Hernandez-Baltazar E, Rivera G . Synthesis and in vitro evaluation of new ethyl and methyl quinoxaline-7-carboxylate 1,4-di-N-oxide against Entamoeba histolytica. Bioorg Med Chem. 2013; 21(15):4550-8. DOI: 10.1016/j.bmc.2013.05.036. View

15.

Escobedo A, Lalle M, Hrastnik N, Rodriguez-Morales A, Castro-Sanchez E, Cimerman S . Combination therapy in the management of giardiasis: What laboratory and clinical studies tell us, so far. Acta Trop. 2016; 162:196-205. DOI: 10.1016/j.actatropica.2016.06.026. View

16.

Lemee V, Zaharia I, Nevez G, Rabodonirina M, Brasseur P, Ballet J . Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France. J Antimicrob Chemother. 2000; 46(5):819-21. DOI: 10.1093/jac/46.5.819. View

17.

Valdez C, Tripp J, Miyamoto Y, Kalisiak J, Hruz P, Andersen Y . Synthesis and electrochemistry of 2-ethenyl and 2-ethanyl derivatives of 5-nitroimidazole and antimicrobial activity against Giardia lamblia. J Med Chem. 2009; 52(13):4038-53. PMC: 2766634. DOI: 10.1021/jm900356n. View

18.

Sherrard J, Wilson J, Donders G, Mendling W, Jensen J . 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge. Int J STD AIDS. 2018; 29(13):1258-1272. DOI: 10.1177/0956462418785451. View

19.

Malla N, Kaul P, Sehgal R, Gupta I . The presence of dsRNA virus in Trichomonas vaginalis isolates from symptomatic and asymptomatic Indian women and its correlation with in vitro metronidazole sensitivity. Indian J Med Microbiol. 2011; 29(2):152-7. DOI: 10.4103/0255-0857.81801. View

20.

Kuhlenschmidt T, Rutaganira F, Long S, Tang K, Shokat K, Kuhlenschmidt M . Inhibition of Calcium-Dependent Protein Kinase 1 (CDPK1) In Vitro by Pyrazolopyrimidine Derivatives Does Not Correlate with Sensitivity of Cryptosporidium parvum Growth in Cell Culture. Antimicrob Agents Chemother. 2015; 60(1):570-9. PMC: 4704151. DOI: 10.1128/AAC.01915-15. View